SCNX

Scienture Holdings, Inc. (SCNX) | Rumor.io

Scienture Holdings

SCNX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,720

Bullish sentiment (50-day avg)68%

Price to earnings ratio0.56

Market capitalization11.1M

Earnings per share-2.03

Dividend yield (TTM)2.2K%

Revenue (annual)431.6K

Net income (annual)-41.5M

Social

What share of all stock conversation is about SCNX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Sep 22

Scienture Holdings, Inc. ($SCNX) announced an exclusive distribution deal with REZENOPY, reaching ~2,000 U.S. addiction treatment clinics.
The deal is expected to generate $4 million in annual revenue, based on conservative estimates of 100 doses per clinic and $20 per dose.
Following the news, $SCNX gained 27.41% in the 10 minutes after the announcement, and institutional ownership increased by 0.94 million shares.

Generated by AI

Sentiment

Of the messages about SCNX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	75% +50	61.11% +4.59	56.52% -16.69	84.94% +11
Bearish	25% -50	38.89% -4.59	43.48% +16.69	15.06% -11

Bullish· Aug 14

The company has reported a 510% sequential revenue growth from Q1 2026, with significant improvements in operating performance, indicating a strong growth trajectory.
The management's goal of achieving profitability in 2027 is likely to be met, with the company's revenue scaling and margins continuing to improve as production scales on both Rezenopy and Arbli.
The stock has the potential for significant upside, with a target price of $1.50-$2.00 possible over the next 5 weeks, and a strong buy signal indicated by the company's impressive revenue growth and improving operating performance.

Bearish· Mar 11

The company has diluted significantly, with a +800% increase in dilution in a year, which may impact investor confidence.
The company's financials are concerning, with a large debt of $2.6M and a total liability of -$22M, which may indicate financial instability.
The company's recent ATM offering and subsequent dilution have likely impacted the stock's momentum, making it difficult for it to break through resistance levels.

Generated by AI

Topics

Of the messages about SCNX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	28.68%
Technical Analysis	—	—	0%	19.82%
Controversies	—	—	0%	0.49%
Earnings	—	—	0%	1.95%
Analysts	—	—	0%	32.08%
Macro	—	—	0%	16.97%

Announcements· Aug 12

Scienture Holdings, Inc. announces the commercial launch and fulfillment of initial purchase orders for REZENOPY, the highest-dose FDA-approved naloxone nasal spray.
The company has successfully fulfilled its initial purchase orders to pharmaceutical wholesalers across the U.S., with nationwide distribution underway.
REZENOPY's commercial launch is backed by a dedicated national sales force, payer coverage extending to over 100 million covered lives, and GPO agreements providing commercial access.

Technical Analysis· Mar 11

$SCNX has broken the descending wedge and VWAP, testing the resistance line at $0.60.
A sub-VWAP cup and handle pattern is forming in $SCNX, indicating a potential move to $0.90-1.
$SCNX needs to break the descending wedge and VWAP to continue its upward momentum, and has a bullish accumulation pattern with green candles and high volume.

Generated by AI

Community

Of the messages about SCNX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	78.26%	60.15%	15.7%
Newcomers	0%	21.74%	39.85%	84.3%

Regulars· Sep 22

The company has secured an exclusive distribution deal for REZENOPY, reaching approximately 2,000 U.S. addiction treatment clinics.
The deal is expected to expand the commercial reach of REZENOPY to addiction treatment centers through an agreement with a distribution partner.
The company's stock price may not be affected by the positive news due to its current financial situation, and it may require a subsequent news announcement to move the price upwards.

Newcomers· Aug 14

Newcomers are focusing on the stock's potential for significant gains, with one user mentioning a +20.49% gain and another predicting a price of $1.
The company's impressive revenue growth is a major point of discussion, with one user highlighting a 510% increase and another noting that the shares have fallen despite this growth.
Users are also discussing the stock's technical analysis, including candlestick patterns and the potential for a "4hr Engulfing" pattern, as well as the stock's safety as a long-term hold due to its growing revenue and cash on hand.

Generated by AI

News

Scienture secures distribution deal for naloxone nasal spray

7d agoInvesting.com

Scienture Holdings Updates Investor Presentation and Guidance

Detailed price information for Scienture Holdings Inc (SCNX-Q) from The Globe and Mail including charting and trades.

15d agoThe Globe and Mail

Scienture Holdings at H.C. Wainwright: growth through niche drugs

15d agoInvesting.com

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base

1mo agoBarchart.com

Scienture Holdings: Q2 Earnings Snapshot

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

1mo agoYahoo Finance

SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product

SCIENTURE has commercially launched REZENOPY, its 10 mg naloxone nasal spray, and fulfilled initial purchase orders to U. S.

1mo agoYahoo Finance

Also Discussed

Investors talking about SCNX also mention

#	Name	Attention
1	Cambium Networks CorporationCMBM	0%0
2	Vsee Health Inc.VSEE	0%0
3	Rani Therapeutics Holdings, Inc. Class A Common StockRANI	0%0
4	TNL Mediagene Ordinary SharesTNMG	0%new
5	Onfolio Holdings, Inc.ONFO	0%-0.05
6	BeneficientBENF	0.01%0
7	Harvard Bioscience Inc.HBIO	0%0
8	Hyperscale Data, Inc. Class A Common StockGPUS	0%0
9	Safe & Green Holdings Corp.SGBX	0%0
10	MSPR - MSP Recovery, Inc.	——

Scienture Holdings, Inc.

Healthcare
Pharmaceutical Retailers

Scienture Holdings, Inc. is a pharmaceutical holding company focused on developing, commercializing, and distributing specialty products that address unmet medical needs. Through its operating businesses, the company works across branded and complex pharmaceutical products, with an emphasis on treatments for cardiovascular and central nervous system conditions, including hypertension, migraine, pain, and thrombosis. Its portfolio combines product development with commercialization and distribution capabilities, supporting both prescription and specialty healthcare markets. Scienture Holdings also serves as a platform for bringing novel drug formulations and delivery systems to patients, physicians, and caregivers, positioning the company within the broader healthcare sector as a niche pharmaceutical operator centered on targeted therapies and product access.

Website

Location

20 Austin Boulevard

Commack, NY, 11725

United States

Social

What share of all stock conversation is about SCNX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Sep 22

Scienture Holdings, Inc. ($SCNX) announced an exclusive distribution deal with REZENOPY, reaching ~2,000 U.S. addiction treatment clinics.
The deal is expected to generate $4 million in annual revenue, based on conservative estimates of 100 doses per clinic and $20 per dose.
Following the news, $SCNX gained 27.41% in the 10 minutes after the announcement, and institutional ownership increased by 0.94 million shares.

Generated by AI

Sentiment

Of the messages about SCNX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	75% +50	61.11% +4.59	56.52% -16.69	84.94% +11
Bearish	25% -50	38.89% -4.59	43.48% +16.69	15.06% -11

Bullish· Aug 14

The company has reported a 510% sequential revenue growth from Q1 2026, with significant improvements in operating performance, indicating a strong growth trajectory.
The management's goal of achieving profitability in 2027 is likely to be met, with the company's revenue scaling and margins continuing to improve as production scales on both Rezenopy and Arbli.
The stock has the potential for significant upside, with a target price of $1.50-$2.00 possible over the next 5 weeks, and a strong buy signal indicated by the company's impressive revenue growth and improving operating performance.

Bearish· Mar 11

The company has diluted significantly, with a +800% increase in dilution in a year, which may impact investor confidence.
The company's financials are concerning, with a large debt of $2.6M and a total liability of -$22M, which may indicate financial instability.
The company's recent ATM offering and subsequent dilution have likely impacted the stock's momentum, making it difficult for it to break through resistance levels.

Generated by AI

Topics

Of the messages about SCNX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	28.68%
Technical Analysis	—	—	0%	19.82%
Controversies	—	—	0%	0.49%
Earnings	—	—	0%	1.95%
Analysts	—	—	0%	32.08%
Macro	—	—	0%	16.97%

Announcements· Aug 12

Scienture Holdings, Inc. announces the commercial launch and fulfillment of initial purchase orders for REZENOPY, the highest-dose FDA-approved naloxone nasal spray.
The company has successfully fulfilled its initial purchase orders to pharmaceutical wholesalers across the U.S., with nationwide distribution underway.
REZENOPY's commercial launch is backed by a dedicated national sales force, payer coverage extending to over 100 million covered lives, and GPO agreements providing commercial access.

Technical Analysis· Mar 11

$SCNX has broken the descending wedge and VWAP, testing the resistance line at $0.60.
A sub-VWAP cup and handle pattern is forming in $SCNX, indicating a potential move to $0.90-1.
$SCNX needs to break the descending wedge and VWAP to continue its upward momentum, and has a bullish accumulation pattern with green candles and high volume.

Generated by AI

Community

Of the messages about SCNX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	78.26%	60.15%	15.7%
Newcomers	0%	21.74%	39.85%	84.3%

Regulars· Sep 22

The company has secured an exclusive distribution deal for REZENOPY, reaching approximately 2,000 U.S. addiction treatment clinics.
The deal is expected to expand the commercial reach of REZENOPY to addiction treatment centers through an agreement with a distribution partner.
The company's stock price may not be affected by the positive news due to its current financial situation, and it may require a subsequent news announcement to move the price upwards.

Newcomers· Aug 14

Newcomers are focusing on the stock's potential for significant gains, with one user mentioning a +20.49% gain and another predicting a price of $1.
The company's impressive revenue growth is a major point of discussion, with one user highlighting a 510% increase and another noting that the shares have fallen despite this growth.
Users are also discussing the stock's technical analysis, including candlestick patterns and the potential for a "4hr Engulfing" pattern, as well as the stock's safety as a long-term hold due to its growing revenue and cash on hand.

Generated by AI

Scienture Holdings

Social

Sep 22

Bullish· Aug 14

Bearish· Mar 11

Announcements· Aug 12

Technical Analysis· Mar 11

Regulars· Sep 22

Newcomers· Aug 14

Scienture secures distribution deal for naloxone nasal spray

Scienture Holdings Updates Investor Presentation and Guidance

Scienture Holdings at H.C. Wainwright: growth through niche drugs

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Scienture Holdings: Q2 Earnings Snapshot

SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product

Also Discussed

Scienture Holdings, Inc.

Company Information

Location

Scienture secures distribution deal for naloxone nasal spray

Scienture Holdings Updates Investor Presentation and Guidance

Scienture Holdings at H.C. Wainwright: growth through niche drugs

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Scienture Holdings: Q2 Earnings Snapshot

SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product

Also Discussed

Social

Sep 22

Bullish· Aug 14

Bearish· Mar 11

Announcements· Aug 12

Technical Analysis· Mar 11

Regulars· Sep 22

Newcomers· Aug 14